4 results
In oral FXa inhibitor-treated patients with acute intracranial bleeding, the objectives of this study are as follows:Primary Efficacy Objective:• To evaluate the effect of andexanet versus usual care on the rate of effective hemostasis.Secondary…
In oral FXa inhibitor-treated patients with acute intracerebral bleeding, the objectives of this study are as follows:Primary Efficacy Objective:To evaluate the effect of andexanet versus usual care on the rate of effective hemostasis.Secondary…
Primary:• Compare progression-free survival (PFS) as assessed by the Independent Review Committee (IRC) per Response Evaluation Criteriain Solid Tumors (RECIST) Version (v) 1.1 in ociperlimab plus tislelizumab (Arm A) versus Durvalumab (Arm C) among…
Primary:• To compare progression free survival (PFS) between Arm A (ociperlimab in combination with tislelizumab) and Arm B (pembrolizumab followed by placebo) in the Intent to Treat (ITT) Analysis Set as assessed by investigators according to…